#TG6002 - Twitter Hashtag

about 4 years ago

#Transgene Confirms the Potential of the Intravenous Route of its #InvirIO #OncolyticViruses against #SolidTumors with #TG6002 Phase I Data Presented at #ESMO22 $TNG https://t.co/OeywBiTNfg

0

1stOncology @1stOncology

about 5 years ago

#Transgene Presents Data From Phase I Clinical Trial Confirming the Potential of the #OncolyticVirus #TG6002 $TNG https://t.co/e62E3VS7Sm

0

1

0

Transgene @TransgeneSA

over 6 years ago

First Patient Dosed with @TRANSGENE’s #TG6002, an oncolytic virus that enables the production of chemotherapy in the tumor

TransgeneSA's tweet photo. First Patient Dosed with @TRANSGENE’s #TG6002, an oncolytic virus that enables the production of chemotherapy in the tumor https://t.co/9uweI4rjxd

0

2

0

Transgene @TransgeneSA

about 8 years ago

@TransgeneSA First patient dosed in phase 1/2 trial #TG6002 for advanced gastrointestinal tumors https://t.co/KBeMPevSJz

TransgeneSA's tweet photo. @TransgeneSA First patient dosed in phase 1/2 trial #TG6002 for advanced gastrointestinal tumors
https://t.co/KBeMPevSJz https://t.co/LOxqkrpSwb

0

2

6

0

Transgene @TransgeneSA

about 8 years ago

@TransgeneSA First patient dosed in phase 1/2 trial #TG6002 for advanced gastrointestinal tumors https://t.co/eiYVe50HTM

TransgeneSA's tweet photo. @TransgeneSA First patient dosed in phase 1/2 trial #TG6002 for advanced gastrointestinal tumors
https://t.co/eiYVe50HTM https://t.co/dbC5aetPgJ

0

3

1

0

Transgene @TransgeneSA

over 8 years ago

#ASCO18 New Pexa-Vec clinical data clearly support the entire Vaccinia-virus based oncolytics pipeline developed by @TransgeneSA #TG6002 #InvirIO https://t.co/geRf81CMke